VX-765: Selective Caspase-1 Inhibitor for Inflammation and Pyroptosis Research

Executive Summary: VX-765 inhibits caspase-1 with high selectivity, reducing IL-1β and IL-18 secretion without affecting IL-6, IL-8, TNFα, or IL-α in preclinical models (ApexBio). It is metabolized in vivo to VRT-043198, which directly inhibits caspase-1 enzymatic activity (Bourne et al., 2025). VX-765 has demonstrated efficacy in models of collagen-induced arthritis, skin inflammation, and HIV-associated CD4 T-cell death. Its selective action enables precise investigation of inflammasome and pyroptosis pathways, distinguishing it from less specific inhibitors. Enzyme assays with VX-765 require buffered pH 7.5 and stabilization additives for optimal results.

Biological Rationale

Caspases are cysteine proteases that regulate programmed cell death and inflammation. The inflammatory caspases—caspase-1, -4, and -5 in humans—process pro-inflammatory cytokines and induce pyroptosis, a form of lytic cell death in macrophages (Bourne et al., 2025). Caspase-1, also known as interleukin-1 converting enzyme (ICE), is essential for converting pro-IL-1β and pro-IL-18 to their active, secreted forms. These cytokines drive inflammatory signaling in response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Dysregulation of caspase-1 activity is implicated in autoimmune diseases, chronic inflammation, and infectious disease pathogenesis. Hence, selective inhibition of caspase-1 is a foundational approach for both basic and translational research on inflammation and cell death (ApexApoptosis).

Mechanism of Action of VX-765

VX-765 is an orally bioavailable prodrug. After absorption, it is rapidly metabolized to VRT-043198, the active compound that selectively and reversibly inhibits caspase-1 activity (ApexBio). VRT-043198 binds to the active site cysteine of caspase-1, preventing autoproteolytic activation and downstream cleavage of IL-1β and IL-18 (Bourne et al., 2025, Table 1). VX-765 does not significantly inhibit apoptotic caspases such as caspase-3, -6, or -7 at pharmacologically relevant concentrations. However, it exhibits moderate activity against caspase-4 and -8 in vitro, with reported IC50 values of approximately 1 μM for caspase-8, compared to sub-micromolar potency for caspase-1 (Bourne et al., 2025, Figure 2).

By blocking caspase-1 activity, VX-765 reduces secretion of mature IL-1β and IL-18, but leaves the synthesis and secretion of other pro-inflammatory cytokines like IL-6, IL-8, and TNFα unaffected. This highly selective cytokine modulation is critical for dissecting the caspase-1-dependent branch of the inflammatory response (Interleukin-II), extending prior reviews by clarifying VX-765’s unique selectivity in cellular contexts.

Evidence & Benchmarks

• VX-765 is metabolized to VRT-043198, which inhibits caspase-1 and prevents IL-1β and IL-18 processing in vitro and in vivo (Bourne et al., 2025).
• In preclinical mouse models of collagen-induced arthritis, oral VX-765 resulted in significant reduction of joint inflammation and cytokine secretion, with no effect on IL-6 or TNFα (ApexBio).
• VX-765 prevents CD4 T-cell pyroptosis in HIV-infected human lymphoid tissues in a dose-dependent manner (1–10 μM) (ApexBio).
• Enzyme inhibition assays confirm VX-765 has an IC50 for human caspase-1 in the low nanomolar range, and an IC50 of ~1 μM for caspase-8, supporting its selectivity profile (Bourne et al., 2025, Table S2).
• VX-765 is insoluble in water, but highly soluble in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonic), enabling flexible assay integration (ApexBio).

Applications, Limits & Misconceptions

VX-765 is a reference compound for dissecting the caspase-1 arm of the inflammasome pathway in both basic and translational research. Major applications include:

• Pyroptosis inhibition in macrophages following bacterial infection (Bourne et al., 2025).
• Modulation of IL-1β and IL-18 in arthritis, skin inflammation, and neuroinflammatory models (ApexBio).
• Study of HIV-associated CD4 T-cell death, where VX-765 reduces pyroptotic cell loss (Caspase-3-7-Inhibitor-I), updating earlier reviews by integrating new HIV tissue data.
• Evaluating therapeutic potential in epilepsy and chronic inflammatory diseases (ApexBio).

Common Pitfalls or Misconceptions

• VX-765 does not inhibit apoptotic caspases (e.g., caspase-3, -6, -7) at relevant concentrations—misuse for pan-caspase inhibition is a common error (Bourne et al., 2025).
• It is not effective for blocking cytokines such as IL-6, IL-8, TNFα, or IL-α—only IL-1β and IL-18 are reduced (ApexBio).
• VX-765 may exhibit moderate off-target activity against caspase-8 and caspase-4 in high-concentration in vitro assays; careful dose selection is essential (Bourne et al., 2025).
• It is insoluble in aqueous buffers; improper solubilization can confound experimental results.
• Long-term solution storage is not recommended due to potential degradation; fresh solutions are advised (ApexBio).

Workflow Integration & Parameters

VX-765 is supplied as a solid form and should be stored desiccated at −20°C. For in vitro assays, dissolve in DMSO or ethanol at the recommended concentrations. Typical working concentrations range from 0.1 μM to 10 μM, depending on the assay system and target cell type. Enzyme inhibition studies are performed at pH 7.5 with stabilizing agents (e.g., DTT). Solutions should be prepared fresh for each experiment to avoid degradation. For cell-based assays, titrate to minimize off-target effects on caspase-4 and -8. Refer to the product page for batch-specific details. For broader strategic use, see the extended workflow notes in Pro-Adrenomedullin, which this article updates by specifying optimal solvents and stability parameters.

Conclusion & Outlook

VX-765 remains a gold-standard, selective caspase-1 inhibitor, uniquely enabling precise modulation of IL-1β and IL-18 in research on inflammation, pyroptosis, and related diseases. It offers substantial advantages over nonselective or irreversible inhibitors by reducing off-target effects and enabling mechanistic clarity. Ongoing trials continue to explore its translational potential. Future research should further delineate its activity spectrum and optimize workflows for emerging disease models. For the latest mechanistic context, see Mouse-IL, contrasted here by integrating new selectivity and solubility benchmarks for VX-765.